| Life Sciences Drew Two Thirds of CT VC in
2006-08
Almost two thirds of
the venture capital investment in Connecticut the past three years has
been in the Life Sciences area, according to a CURE analysis of figures
in the MoneyTree™ report, supplied by PricewaterhouseCoopers and the
National Venture Capital Association, based on data provided by Thomson
Reuters.
A total of $687.1
million of venture capital was invested in Connecticut during the years
2006-08, according to the MoneyTree™ report. Of that, $450.3 million,
or almost 66%, was in the Life Sciences, which includes Biotech and
Medical Devices.
Total investment in
all Connecticut industries was down in 2008 compared with prior years,
but included investment in SurgiQuest, Carigent Therapeutics, Cara
Therapeutics, Optherion, Pequot Enzyme Rx, and Affomix.
Details are as
follows.
CT Life Science
Venture Capital Investments: Detail by Quarter and Type
|
|
|
Company
|
$
|
| 2008
Medical Devices |
Q4 |
SurgiQuest, Inc. |
9,500,000
|
| 2008
Medical Devices |
Q4 |
Carigent Therapeutics, Inc. |
600,000
|
|
Total
Q4
|
|
|
10,100,000
|
| |
|
|
|
| 2008
Biotechnology |
Q3 |
Cara Therapeutics, Inc. |
12,300,000
|
|
Total
Q3
|
|
|
12,300,400
|
| |
|
|
|
| 2008
Biotech |
Q2 |
Optherion, Inc. |
15,000,000
|
| 2008
Medical Devices |
Q2 |
SurgiQuest, Inc. |
4,750,000
|
|
Total
Q2
|
|
|
19,750,000
|
| |
|
|
|
|
2008
Biotech
|
Q1
|
Pequot
EnzymeRx
|
14,000,000
|
|
2008
Biotech
|
Q1
|
Affomix
|
7,000,000
|
|
Total
Q1
|
|
|
21,000,000
|
|
Total
Year
|
|
|
63,150,400
|
| |
|
|
|
|
2007
Biotech
|
Q1
|
RainDance
Technologies
|
23,655,000
|
|
2007
Biotech
|
Q1
|
Cara
Therapeutics
|
5,000,000
|
|
2007
Biotech
|
Q2
|
Spine
Wave
|
45,000,200
|
|
2007
Biotech
|
Q2
|
BioRelix
|
25,750,200
|
|
2007
Biotech
|
Q3
|
Optherion
|
10,000,000
|
|
2007
Biotech
|
Q3
|
Genomas
|
2,500,000
|
|
2007
Biotech
|
Q3
|
REN
Pharmaceuticals
|
1,000,000
|
|
2007
Biotech
|
Q4
|
Optherion
|
26,999,700
|
|
2007
Biotech
|
Q4
|
Carigent
Therapeutics
|
2,000,000
|
|
Total
Year
|
|
|
141,905,100
|
|
|
|
|
|
|
2007
Medical Devices
|
Q1
|
Stevens
Proof of Concept
|
500,000
|
|
2007
Medical Devices
|
Q1
|
Applied
Spine Technologies
|
15,000,000
|
|
2007
Medical Devices
|
Q2
|
Applied
Spine Technologies
|
13,000,000
|
|
2007
Medical Devices
|
Q3
|
HistoRx
|
6,552,000
|
|
2007
Medical Devices
|
Q4
|
Ikonisys
|
20,000,000
|
|
2007
Medical Devices
|
Q4
|
HistoRx
|
2,280,000
|
|
Total
Year
|
|
|
67,332,000
|
| Total
2007 Life Science |
|
|
209,237,100 |
CT Life Science
Venture Capital Investments by Type
|
|
2006
|
2007
|
2008
|
|
|
Deals
|
$
|
Deals
|
$
|
Deals
|
$
|
|
Biotech
|
9
|
146,600,800
|
9
|
145,589,300
|
3
|
34,300,400
|
|
Medical
Devices
|
2
|
15,000,000
|
7
|
69,332,000
|
3
|
15,787,000
|
|
Other*
|
|
|
1 |
23,655,000 |
|
|
|
TOTAL
(Life Sciences)
|
11
|
161,600,800
|
17
|
238,576,300
|
6
|
50,087,400
|
* RainDance
Technologies of Guilford
CT Venture
Capital Investments by Quarter
|
Quarter
|
# of Deals
|
Investment
Amount
|
Life Sciences Amount
|
% Life Sciences
|
| Q4 2008 |
9 |
$15.1 million |
$10.1 million |
67%
|
| Q3 2008 |
9 |
$48.3 million |
$12.3 million |
25%
|
| Q2 2008 |
9 |
$43.9 million |
$20.7 million |
47%
|
| Q1 2008 |
7 |
$20.1 million |
$7.0
million
|
35%
|
| Q4 2007 |
12 |
$76.1
million
|
$61.3
million
|
81%
|
| Q3 2007 |
8 |
$36.8
million
|
$19.1
million
|
52%
|
| Q2 2007 |
8 |
$107.6
million
|
$88.5
million
|
82%
|
| Q1 2007 |
7 |
$
75.3 million
|
$46.0
million
|
61%
|
| Q4 2006 |
6 |
$39.3
million
|
$20.1
million
|
52%
|
|
Q3 2006
|
10
|
$56.4
million
|
$21.5
million
|
38%
|
|
Q2 2006
|
9
|
$111.7
million
|
$68.7
million
|
62%
|
|
Q1 2006
|
6
|
$56.6
million
|
$51.3
million
|
91%
|
CT Venture
Capital Investments by Year
|
Year
|
# of Deals
|
Investment Amount
|
Life Sciences Amount
|
% Life Sciences
|
| 2008 |
34
|
$127.4
million
|
$50.1 million |
39% |
| 2007 |
37
|
$295.8
million
|
$238.6 million |
81% |
| 2006 |
31
|
$263.9
million
|
$161.6 million |
61% |
|
2005
|
31
|
$192.8
million
|
|
|
|
2004
|
32
|
$195.9
million
|
|
|
|
2003
|
34
|
$203.8
million
|
|
|
|
2002
|
38
|
$182.7
million
|
|
|
| 2001 |
70
|
$549.8
million
|
|
|
|
